Know Cancer

or
forgot password

Preoperative Transhepatic Arterial Chemotherapy in the Treatment of Liver Metastasis of Resectable Colorectal Cancer


Phase 4
18 Years
75 Years
Open (Enrolling)
Both
Colorectal Cancer

Thank you

Trial Information

Preoperative Transhepatic Arterial Chemotherapy in the Treatment of Liver Metastasis of Resectable Colorectal Cancer


We administered TAC(oxaliplatin,FUDR and MMC) 7 days before liver metastasis resection of
colorectal cancer. The study endpoints were progression free survival and overall survival
as evaluated by intent-to-treat analysis.


Inclusion Criteria:



- age <= 75 years

- resectable liver metastasis

- remnant liver volume >= 70%

- without other organ metastasis or peritoneum metastasis

- without contradiction of cardiac and pulmonary diseases

Exclusion Criteria:

- age > 75 years

- unresectable liver metastasis

- remnant liver volume < 50%

- with other organ metastasis or peritoneum metastasis

- with contradiction of cardiac and pulmonary diseases

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

progression free survival

Outcome Time Frame:

5 years after operation

Safety Issue:

No

Principal Investigator

jianmin xu, MD, PHD

Investigator Role:

Principal Investigator

Investigator Affiliation:

department of general surgery, zhongshan hospital, fudan university

Authority:

China: Ministry of Health

Study ID:

2009-04

NCT ID:

NCT00874406

Start Date:

January 2008

Completion Date:

December 2009

Related Keywords:

  • Colorectal Cancer
  • colorectal cancer
  • liver metastasis
  • neoadjuvant chemotherapy
  • Colorectal Neoplasms
  • Neoplasm Metastasis
  • Liver Neoplasms

Name

Location